These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Dysfunction in multiple primary afferent fiber subtypes revealed by quantitative sensory testing in patients with chronic vincristine-induced pain. Dougherty PM; Cata JP; Burton AW; Vu K; Weng HR J Pain Symptom Manage; 2007 Feb; 33(2):166-79. PubMed ID: 17280922 [TBL] [Abstract][Full Text] [Related]
3. Bortezomib-induced cutaneous lesions in multiple myeloma patients: a case report. Rodríguez-Martín M; Sáez-Rodríguez M; García-Bustínduy M; Martín-Herrera A; Noda-Cabrera A Dermatol Online J; 2008 Nov; 14(11):14. PubMed ID: 19094852 [TBL] [Abstract][Full Text] [Related]
4. Use of bortezomib in B-cell non-Hodgkin's lymphoma. Wang M; Zhou Y; Zhang L; Nguyen CA; Romaguera J Expert Rev Anticancer Ther; 2006 Jul; 6(7):983-91. PubMed ID: 16831071 [TBL] [Abstract][Full Text] [Related]
6. [Safety evaluation of bortezomib in multiple myeloma patients with severe renal failure]. Muta T; Nakanishi H; Yasunaga M; Senba S; Murakami H; Kan S; Ueda Y; Fujisaki T Gan To Kagaku Ryoho; 2011 Feb; 38(2):237-41. PubMed ID: 21368487 [TBL] [Abstract][Full Text] [Related]
7. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Badros A; Goloubeva O; Dalal JS; Can I; Thompson J; Rapoport AP; Heyman M; Akpek G; Fenton RG Cancer; 2007 Sep; 110(5):1042-9. PubMed ID: 17654660 [TBL] [Abstract][Full Text] [Related]
8. From bench to bedside: a case of rapid reversal of bortezomib-induced neuropathic pain by the TRPM8 activator, menthol. Colvin LA; Johnson PR; Mitchell R; Fleetwood-Walker SM; Fallon M J Clin Oncol; 2008 Sep; 26(27):4519-20. PubMed ID: 18802169 [No Abstract] [Full Text] [Related]
9. Bortezomib-induced perivascular dermatitis in a patient with multiple myeloma. Ozkurt ZN; Sucak GT; Aki SZ; Yağci M; Erdem O Cutan Ocul Toxicol; 2009; 28(3):141-3. PubMed ID: 19548772 [TBL] [Abstract][Full Text] [Related]
13. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comparison between previously treated and untreated patients. Corso A; Mangiacavalli S; Varettoni M; Pascutto C; Zappasodi P; Lazzarino M Leuk Res; 2010 Apr; 34(4):471-4. PubMed ID: 19674790 [TBL] [Abstract][Full Text] [Related]
14. Immune-mediated neuropathies in myeloma patients treated with bortezomib. Ravaglia S; Corso A; Piccolo G; Lozza A; Alfonsi E; Mangiacavalli S; Varettoni M; Zappasodi P; Moglia A; Lazzarino M; Costa A Clin Neurophysiol; 2008 Nov; 119(11):2507-12. PubMed ID: 18829381 [TBL] [Abstract][Full Text] [Related]
15. Rapid improvement in renal function in patients with multiple myeloma and renal failure treated with bortezomib. Qayum A; Aleem A; Al Diab AR; Niaz F; Al Momen AK Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):63-8. PubMed ID: 20061695 [TBL] [Abstract][Full Text] [Related]
16. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Richardson PG; Sonneveld P; Schuster MW; Stadtmauer EA; Facon T; Harousseau JL; Ben-Yehuda D; Lonial S; Goldschmidt H; Reece D; Bladé J; Boccadoro M; Cavenagh JD; Boral AL; Esseltine DL; Wen PY; Amato AA; Anderson KC; San Miguel J Br J Haematol; 2009 Mar; 144(6):895-903. PubMed ID: 19170677 [TBL] [Abstract][Full Text] [Related]